• Lipo3K Transfection Reagent: Mechanistic Insights & Experime

  2026-05-28

  Explore the advanced mechanism and unique assay advantages of Lipo3K Transfection Reagent. This article reveals how its dual-component design and low cytotoxicity optimize transfection for challenging cell systems.

• (S)-(+)-Dimethindene maleate: Technical Guide for M2 Antagon

  2026-05-27

  (S)-(+)-Dimethindene maleate provides selective inhibition of M2 muscarinic and H1 histamine receptors, enabling precise interrogation of autonomic, cardiovascular, and respiratory pathways in preclinical research. It is not suitable for diagnostic or medical use, and its solution stability requires careful handling for reproducible results.

• β-Adrenergic Blockade and Hematopoietic Regeneration Post-HC

  2026-05-27

  This study reveals that nonselective β-adrenergic receptor blockers, such as carvedilol, impair hematopoietic regeneration after hematopoietic cell transplantation (HCT) in mice and humans, while β1-selective inhibition with metoprolol does not. The findings clarify the selective roles of adrenergic receptor subtypes in bone marrow recovery and inform clinical strategies for managing β-blocker therapy in HCT patients.

• Anlotinib Hydrochloride: Redefining Multi-Target Angiogenesi

  2026-05-26

  This thought-leadership article dissects the mechanistic power and translational advantages of Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor. Drawing from seminal preclinical evidence and contemporary assay intelligence, it guides cancer researchers through experimental best practices, competitive positioning, and the practical realities of endothelial cell migration inhibition and capillary tube formation assays. Building on the robust literature and comparative analysis, this discussion advances beyond standard product descriptions to deliver actionable, evidence-based strategies for translational oncology.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-26

  CUDC-907 is a dual PI3K and HDAC inhibitor for in vitro research, enabling targeted studies of cell signaling, cell cycle arrest, and apoptosis in cancer models. It is intended for controlled laboratory workflows and should not be used for diagnostic or therapeutic purposes.

• Tin Mesoporphyrin IX (chloride): Precision Inhibition and HO

  2026-05-25

  Explore Tin Mesoporphyrin IX (chloride) as a precision tool for dissecting heme oxygenase activity in metabolic and viral disease research. This article uniquely bridges mechanistic inhibition, advanced assay design, and emerging insights from HO-1 modulation.

• Grazoprevir/Elbasvir for HCV: Advances in Direct-Acting Anti

  2026-05-25

  The reference review details the clinical impact of the grazoprevir/elbasvir fixed-dose combination, highlighting its efficacy and tolerability in chronic hepatitis C virus (HCV) infection. The innovation lies in interferon-free regimens that achieve high sustained virologic response (SVR) rates, including in challenging populations such as those with HIV/HCV coinfection or chronic kidney disease.

• BRD4 Inhibition Potentiates Ferroptosis via ROS and FSP1 Mod

  2026-05-24

  The referenced study demonstrates that BRD4 inhibitors, including I-BET-762, markedly enhance erastin-induced ferroptosis across diverse cell lines by promoting ROS accumulation and suppressing FSP1 expression. This work clarifies the mechanistic role of BRD4 in ferroptosis regulation and suggests new combinatorial strategies for cancer therapy.

• Scalable iMSC-EV Biomanufacturing for Pulmonary Fibrosis The

  2026-05-23

  Gong et al. present a robust, scalable platform for producing extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs) derived from extended pluripotent stem cells (EPSCs), addressing key barriers in regenerative EV therapies. This study demonstrates that iMSC-EVs match primary MSC-EVs in therapeutic efficacy, offering a practical path toward standardized, GMP-compliant cell-free therapies for fibrotic disease.

• BMS-345541: Redefining NF-κB Modulation in Translational Res

  2026-05-22

  Explore how BMS-345541 (free base) enables precise IKK-1/IKK-2 inhibition, bridging mechanistic insights with translational strategy for inflammation, cancer, and vascular biology.

• Palomid 529 (P529): Precision Inhibition of PI3K/Akt/mTOR in

  2026-05-22

  Palomid 529 (P529) enables researchers to dissect and target the PI3K/Akt/mTOR axis with unmatched specificity, making it crucial for investigating metastasis and chemoresistance in esophageal squamous cell carcinoma (ESCC). This article translates cutting-edge mechanistic insights into practical workflow guidance, with protocol details, troubleshooting, and strategic interlinks to empower translational oncology and beyond.

• (S)-(+)-Dimethindene maleate: Technical Guide for M2 Antagon

  2026-05-21

  (S)-(+)-Dimethindene maleate is a selective M2 muscarinic and H1 histamine receptor antagonist designed to support research into autonomic regulation, cardiovascular, and respiratory system function. It provides a defined tool for receptor selectivity studies but should not be used for diagnostic or clinical purposes. Researchers benefit from its solubility, purity, and workflow reliability, while adhering to well-documented storage and handling protocols.

• Dual-Action Airway Stent Suppresses Tracheal Restenosis in V

  2026-05-21

  Zhao et al. engineered a novel airway stent combining anti-inflammatory and anti-angiogenic agents to address tracheal in-stent restenosis (TISR), a persistent complication in airway interventions. Their integrated approach demonstrated effective suppression of fibrosis, angiogenesis, and infection in a rabbit model, with transcriptomic evidence supporting durable modulation of pro-inflammatory and pro-fibrotic pathways.

• Pulchinenoside B4 Mitigates Colitis via CD1d/NLRP3 in Macrop

  2026-05-20

  This study demonstrates that Pulchinenoside B4 (PB4) alleviates DSS-induced colitis in mice by targeting CD1d and inhibiting NLRP3 inflammasome activation specifically in macrophages. The findings highlight a targeted anti-inflammatory mechanism, paving the way for novel therapeutic strategies for ulcerative colitis.

• (S)-(+)-Dimethindene maleate for M2 Muscarinic Antagonism

  2026-05-20

  (S)-(+)-Dimethindene maleate is a highly selective M2 muscarinic receptor antagonist with additional H1 histamine receptor blocking activity, making it suitable for research into autonomic regulation, cardiovascular, and respiratory physiology. It should not be used in diagnostic or medical applications, and its use is limited to experimental settings that require precise receptor selectivity profiling.

8139 records 13/543 page Previous Next First page 上5页 1112131415 下5页 Last page